Hoth Therapeutics (NASDAQ:HOTH) announced on Tuesday, April 14, 2026, positive preclinical results for its HT-VA program, showing that parenteral administration of Glial Cell-Derived Neurotrophic Factor (GDNF) can fundamentally alter liver fat metabolism.
The data suggests the therapy may provide a potent alternative to existing treatments for metabolic-associated fatty liver disease (MAFLD) and obesity.
The study’s key findings centered on the genetic reprogramming of liver cells.
Researchers observed a statistically significant reduction in the expression of Srebf1, a master regulator of fat synthesis, alongside a marked increase in Pparα, a protein essential for the breakdown of fatty acids.
These genetic shifts indicate that the treatment not only reduces existing fat but may also prevent the formation of new lipids at a molecular level.
In a direct comparison, Hoth reported that HT-VA showed superior gene-expression improvements over semaglutide, the active ingredient in blockbuster weight-loss drugs.
While semaglutide is widely recognized for its appetite-suppression capabilities, Hoth’s data suggests that GDNF provides a more direct metabolic intervention within the liver tissue itself.
Looking ahead, Hoth intends to conduct further preclinical validation to solidify the safety and efficacy profile of the treatment.
The company is currently evaluating potential clinical development pathways specifically targeting MAFLD and obesity, two markets with high unmet medical needs.
To expedite this process, management indicated it is open to strategic partnerships that could provide the resources necessary to transition HT-VA from the laboratory to human clinical trials.